Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation Of Biomarker Cohort In FORTITUDE Trial For Delpacibart Braxlosiran In People Living With Facioscapulohumeral Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Avidity Biosciences is advancing its FORTITUDE trial for delpacibart braxlosiran, targeting facioscapulohumeral muscular dystrophy, with a new biomarker cohort. The company aims for accelerated approval, with enrollment expected to complete by 1H 2025.
October 30, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avidity Biosciences has initiated a biomarker cohort in its FORTITUDE trial for delpacibart braxlosiran, targeting FSHD. The company is pursuing accelerated approval, with enrollment expected to complete by 1H 2025.
The initiation of a biomarker cohort and pursuit of accelerated approval for delpacibart braxlosiran could positively impact Avidity Biosciences' stock. Successful trial progress and potential approval are significant milestones for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100